Solid Biosciences (NASDAQ: SLDB) grants 77,500 director stock options

Rhea-AI Filing Summary

Solid Biosciences Inc. reported that director Nagendran Sukumar received a grant of stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and expire on June 10, 2036.

The grant vests in full on the earlier of the one-year anniversary of June 10, 2026 or immediately before the company’s next annual stockholder meeting after that date. Any remaining unvested portion will also vest automatically upon specified change in control events, aligning the director’s compensation with company performance and potential strategic transactions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nagendran Sukumar

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	77,500	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 77,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 77,500 options Exercise price: $6.61 per share Expiration date: June 10, 2036 +2 more

5 metrics

Option grant size 77,500 options Director stock option grant to Nagendran Sukumar

Exercise price $6.61 per share Exercise price of director stock option grant

Expiration date June 10, 2036 Option term for director stock option grant

Shares underlying options 77,500 shares Common stock underlying granted options

Vesting trigger Earlier of one year or next annual meeting Vesting schedule for director option grant

Key Terms

Director Stock Option, grant/award acquisition, exercise price, change in control events

4 terms

Director Stock Option financial

"security_title: "Director Stock Option (Right to Buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

exercise price financial

"conversion_or_exercise_price: "6.6100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control events financial

"will vest automatically as to 100% ... upon specified change in control events"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nagendran Sukumar

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MASSACHUSETTS 02129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$6.61	06/10/2026		A		77,500		(1)	06/10/2036	Common Stock	77,500	$0.00	77,500	D

Explanation of Responses:

1. This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

	/s/ Kimberly Cornwell as attorney-in-fact for Sukumar Nagendran	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Solid Biosciences (SLDB) disclose in this Form 4 filing?

Solid Biosciences disclosed that director Nagendran Sukumar received a grant of stock options for 77,500 shares. These options are part of his director compensation and give him the right to buy common stock at a fixed exercise price in the future.

How many stock options did Nagendran Sukumar receive from Solid Biosciences (SLDB)?

Nagendran Sukumar received stock options on 77,500 shares of Solid Biosciences common stock. This entire amount reflects a single grant made as director compensation, increasing his potential future equity stake if he chooses to exercise the options.

What is the exercise price of the new Solid Biosciences (SLDB) director options?

The newly granted director stock options have an exercise price of $6.61 per share. This means Sukumar can buy up to 77,500 shares at $6.61 each once the options vest, regardless of the market price at that time.

When do Nagendran Sukumar’s Solid Biosciences (SLDB) options vest?

The options vest in full on the earlier of the one-year anniversary of June 10, 2026 or immediately prior to Solid Biosciences’ next annual stockholder meeting after that date. This structure links vesting to both time and the company’s annual governance cycle.

Do the Solid Biosciences (SLDB) director options have change in control protection?

Yes. Any unvested portion of the option will vest automatically upon specified change in control events. This provision ensures the director’s compensation opportunity is preserved if Solid Biosciences undergoes a qualifying merger, acquisition, or similar control transaction before normal vesting.

When do the newly granted Solid Biosciences (SLDB) options expire?

The director stock options expire on June 10, 2036. After that date, any unexercised options will lapse and can no longer be used to purchase Solid Biosciences common stock, giving the director a long-term window to decide if and when to exercise.